Tag: Covid Vaccine

India's vaccination coverage against coronavirus under the mass vaccination drive has crossed the landmark of 63 crore. Over 73 lakh doses have been administered in the last 24 hours.

The antibody responses of individuals with confirmed pre-vaccination SARS-CoV-2 infection were compared with those individuals without prior evidence of infection.

Gennova submitted the proposed Phase 2 and 3 study titled 'A Prospective, Multicentre, Randomised, Active-controlled, Observer-blind, Phase II study seamlessly followed by a Phase III study to evaluate the Safety, Tolerability, and Immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy subjects' which was approved by the office of the DCGI, CDSCO.

A study showed a robust antibody response in blood and breast milk of lactating mothers vaccinated against Covid-19, which may help protect nursing infants from the illness

Among some people with weak immune systems, the response of two doses of Covid vaccine remains low or absent, according to a study.

Schools across the country were closed in March last year ahead of a nationwide lockdown to contain the spread of novel coronavirus infection.

A day after getting the emergency use authorisation (EUA) in India, country's leading multinational pharmaceutical company Zydus Cadila has said that the commercial rollout of its ZyCoV-D vaccine will start from mid-September. The pharma major informed about the future rollout plan in a virtual press conference held on Saturday.

India's drug regulator on Friday approved Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above.

The Drugs Controller General of India (DCGI) has granted authorization to Zydus Cadila's three-dose COVID-19 vaccine ZyCoV-D for emergency use in India.

Ghebreyesus called out on manufacturers and leaders to prioritise supply to low- and middle-income countries over booster shots, to help bridge the gap between the haves and have nots.

The Odisha government has directed the authorities to ensure the complete vaccination of people belonging to Tibetan communities residing in the State.

Cumulatively, 19,45,18,646 people in the 18-44 age group across all states and union territories have received their first dose and 1,51,14,678 have received their second dose since the start of phase-3 of the vaccination drive, it said.

The regulatory approval has been received for conducting "Phase 2 randomised, multi-centric, clinical trial of heterologous prime-boost combination of SARS-CoV-2 vaccines to evaluate the immunogenicity and safety of BBV152 (Covaxin) with BBV154 (Adenoviral Intranasal Covid-19 vaccine) in healthy volunteers.

The team evaluated the SARS-CoV-2 spike immunoglobulin (Ig) G antibody levels after 1 and 2 BNT162b2 doses in previously infected individuals compared with those without previous infection.

The ministry said 22,93,781 beneficiaries in the age group of 18-44 years were administered the first dose, while 4,32,281 received the second dose of the vaccine on Friday.